We aim to develop new radioisotope-labelled compounds for the imaging of tumour biology.
Sponsor: University of Oxford
ClinicalTrials.gov Number: NCT02024009
EudraCT number: 2013-004968-56
Systemic therapy and Chemoradiation in Advanced LOcalised Pancreatic cancer – 2
Full title: A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/- nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer
Our group aims to identify novel therapies that target subgroups of lung cancer patients harbouring specific genetic changes.
The focus of the group is on tumour angiogenesis and the role of notch signalling, and hypoxia biology and its regulation.
Investigating post-transcriptional mechanisms that drive cancer behaviour and researching novel cancer therapeutics for patients with advanced malignancies.
We are studying the role of insulin-like growth factor (IGF) signalling in tumour biology, aiming to use this information to develop new ways to prevent and treat cancer.
Delivering the right treatment to the right patient at the right time.
Our group objective is to identify novel pathways governing cell proliferation, which are altered in cancers, to provide insights into drug resistance and predict response to chemotherapy and ionizing radiation.
We design and synthesise chemically modified DNA for diagnostic and therapeutic applications.
The aim or our research is to understand how genome stability is maintained in response to DNA double-strand breaks, and to exploit our findings to target cancer.